Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2011-04-26
2011-04-26
Chen, Stacy B (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C424S205100, C424S215100
Reexamination Certificate
active
07932074
ABSTRACT:
The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.
REFERENCES:
patent: 4571385 (1986-02-01), Greenberg et al.
patent: 6113910 (2000-09-01), Clark et al.
Bernstein et al. Lancet. 1999; 354: 287-290.
Wandstradt et al. Ann Pharmacother. 1999 ; 33 (7-8): 833-9, abstract only.
Brussow et al. Journal of General Virology. 1990; 71 (Pt 11): 2625-30, abstract only.
Hoshino et al. Journal of Medical Virology, Apr. 1997: 51: 319-325.
Midthun et al. Journal of Virology 1985, 53 (3): 949-954
Midthun et al. Journal of Clinical Microbiology. 1986. 24 (5): 822-826.
Gouvea et al., Identification of bovine and porcine rotavirus G types by PCR, Journal of Clinical Microbiology, 1994, 32(5): 1338-1340.
Clark et al., Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3, J. Infect. Dis., 1990, 161(6):1099-104.
Woode et al., “The Isolation of a Reovirus-Like Agent Associated with Diarrhoea in Colostrum-Deprived Calves in Great Britain,”Research in Veterinary Science16:102-105 (1974).
Bridger and Woode, “Neonatal Calf Diarrhoea: Identification of a Reovirus-Like (Rotavirus) Agent in Faeces by Immunofluorescence and Immune Electron Microscopy,”The British Veterinary Journal131:528-535 (1975).
Banatvala et al., “Rotaviral Infections in Human Neonates,”The Journal of the American Veterinary Association173:527-530 (1978).
Wyatt et al., “Reovirus-like Agents (Rotaviruses) Associated with Diarrheal Illness in Animals and Man.”Perspectives in Virology10:121-145 (1978).
Wyatt et al., “Human Rotavirus Type 2: Cultivation in vitro,”Science207:189-191 (1980).
Vesikari et al., “Immunogenicity and Safety of Live Oral Attenuated Bovine Rotavirus Vaccine Strain RIT 4237 in Adults and Young Children,”Lancet2:807-811 (1983).
Hoshino et al., “Serotypic Characterization of Rotaviruses Derived from Asymptomatic Human Neonatal Infections,”Journal of Clinical Microbiology21:425-430 (1985).
Kapikian et al., “Rhesus Rotavirus: A Candidate Vaccine for Prevention of Human Rotavirus Disease,” Vaccines 85, Lerner et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 357-367 (1985).
Midthun et al., “Reassortant Rotaviruses as Potential Live Rotavirus Vaccine Candidates,”Journal of Virology53:949-954 (1985).
Vesikari et al., “Dose-Response Study of RIT 4237 Oral Rotavirus Vaccine in Breast-Fed and Formula-Fed Infants,”Pediatric Infectious Diseases4:622-625 (1985).
Clark et al., “Immune Response of Infants and Children to Low-Passage Bovine Rotavirus (Strain WC3),”The American Journal of Diseases of Children140:350-356 (1986).
Midthun et al., “Single Gene Substitution Rotavirus Reassortants Containing the Major Neutralization Protein (VP7) of Human Rotavirus Serotype 4,”Journal of Clinical Microbiology24:822-826 (1986).
Vesikari et al., “A Comparative Trial of Rhesus Monkey (RRV-1) and Bovine (RIT 4237) Oral Rotavirus Vaccines in Young Children.”The Journal of Infectious Diseases153:832-839 (1986).
Halsey et al., “Human-Rhesus Reassortant Rotavirus Vaccines: Safety and Immunogenicity in Adults, Infants, and Children,”The Journal of Infectious Diseases158:1261-1267 (1988).
Kapikian et al., “Development of a Rotavirus Vaccine by a “Jennerian” and a Modified “Jennerian” Approach,” Vaccines 88, Chanock et al., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. pp. 151-159 (1988).
Flores et al., “Reactions to and Antigenicity of Two Human-Rhesus Rotavirus Reassortant Vaccine Candidates of Serotypes 1 and 2 in Venezuelan Infants,”Journal of Clinical Microbiology27:512-518 (1989).
Midthun et al., “Comparison of Immunoglobulin A (IgA), IgG, and IgM Enzyme-linked Immunosorbent Assays. Plaque Reduction Neutralization Assay, and Complement Fixation in Detecting Seroresponses to Rotavirus Vaccine Candidates,”Journal of Clinical Microbiology27:2799-2804 (1989).
Bernstein et al., “Evaluation of WC3 Rotavirus Vaccine and Correlates of Protection in Healthy Infants,”The Journal of Infectious Diseases162:1055-1062 (1990).
Clark et al., “Immune Protection of Infants against Rotavirus Gastroenteritis by a Serotype 1 Reassortant of Bovine Rotavirus WC3,”The Journal of Infectious Diseases161:1099-1104 (1990).
Clark et al., “Serotype 1 Reassortant of Bovine Rotavirus WC3, Strain WI79-9, Induces a Polytypic Antibody Response in Infants,”Vaccine8:327-332 (1990).
Flores et al., “Comparison of Reactogenicity and Antigenicity of M37 Rotavirus Vaccine and Rhesus-Rotavirus-Based Quadrivalent Vaccine,”Lancet336:330-334 (1990).
Green et al., “Homotypic and Heterotypic Epitope-Specific Antibody Responses in Adult and Infant Rotavirus Vaccines: Implications for Vaccine Development,”The Journal of Infectious Diseases161:667-679 (1990).
Nakagomi et al., “Isolation and Molecular Characterization of a Serotype 9 Human Rotavirus Strain,”Microbiology and Immunology34:77-82 (1990).
Perez-Schael et al., “Clinical Studies of a Quadrivalent Rotavirus Vaccine in Venezuelan Infants,”Journal of Clinical Microbiology28:553-558 (1990).
Taniguchi et al., “Antibody Response to Serotype-Specific and Cross-Reactive Neutralization Epitopes on VP4 and VP7 after Rotavirus Infection or Vaccination,”Journal of Clinical Microbiology29:483-487 (1991).
Kapikian et al. “An Update on the “Jennerian” and Modified “Jennerian” Approach to Vaccination of Infants and Young Children against Rotavirus Diarrhea,”Advances in Experimental Medicine and Biology327:59-69 (1992).
Madore et al., “Field Trial of Rhesus Rotavirus or Human-Rhesus Rotavirus Reassortant Vaccine of VP7 Serotype 3 or 1 Specificity in Infants,”The Journal of Infectious Diseases166:235-243 (1992).
Christy et al., “Evaluation of a Bovine-Human Rotavirus Reassortant Vaccine in Infants,”The Journal of Infectious Diseases168:1598-1599 (1993).
Flores et al., “Reactogenicity and Immunogenicity of a High-Titer Rhesus Rotavirus-Based Quadrivalent Rotavirus Vaccine,”Journal of Clinical Microbiology31:2439-2445 (1993).
Vesikari, “Clinical Trials of Live Oral Rotavirus Vaccines: the Finnish Experience,”Vaccine11:255-261 (1993).
Simasathien et al., “Vaccination of Thai Infants with Rhesus-Human Reassortant Tetravalent Oral Rotavirus Vaccine,”The Pediatric Infectious Disease Journal13:590-596 (1994).
Vesikari, “Bovine Rotavirus-Based Rotavirus Vaccines in Humans,”Viral Infections of the Gastrointestinal Tract, Kapikian, ed., Marcel Dekker, Inc., New York pp. 419-442 (1994).
Kapikian, “Rhesus Rotavirus-Based Human Rotavirus Vaccines and Observations on Selected Non-Jennerian Approaches to Rotavirus Vaccination,”Viral Infections of the Gastrointestinal Tract, Kapikian, ed., Marcel Dekker, Inc., New York pp. 443-470 (1994).
Bernstein et al., “Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children,”Journal of the American Medical Association273:1191-1196 (1995).
Treanor et al., “Evaluation of the Protective Efficacy of a Serotype 1 Bovine-Human Rotavirus Reassortant Vaccine in Infants,”The Pediatric Infectious Disease Journal14:301-307 (1995).
Clark et al., “The Development of Multival
Chanock Robert M.
Hoshino Yasutaka
Kapikian Albert Z.
Chen Stacy B
Kilpatrick Townsend & Stockton LLP
Kinsey White Nicole
The United States of America as represented by the Department of
LandOfFree
Multivalent human-bovine rotavirus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent human-bovine rotavirus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent human-bovine rotavirus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691806